X4 Pharmaceuticals Inc. (XFOR) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    X4 Pharmaceuticals Inc.

    NASDAQ: XFOR · Real-Time Price · USD
    3.64
    0.52 (16.67%)
    At close: Sep 04, 2025, 3:59 PM
    3.65
    0.27%
    Pre-market: Sep 05, 2025, 07:02 AM EDT

    X4 Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 2.56M n/a n/a n/a
    Cost of Revenue
    		 797K 2M 1.99M 1.89M
    Gross Profit
    		 1.76M -2M -1.99M -1.89M
    Operating Income
    		 -36.4M -107.52M -87.57M -85.11M
    Interest Income
    		 5.77M 4.58M 219K 10K
    Pretax Income
    		 -37.14M -101.09M -93.84M -88.68M
    Net Income
    		 -37.45M -101.17M -93.87M -88.7M
    Selling & General & Admin
    		 61.52M 35.51M 27.02M 24.7M
    Research & Development
    		 81.64M 72.02M 61.06M 50.65M
    Other Expenses
    		 -105M n/a -509K 9.76M
    Operating Expenses
    		 38.16M 107.52M 87.57M 85.11M
    Interest Expense
    		 8.77M 5.78M 3.99M 3.64M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 38.96M 107.52M 87.57M 85.11M
    Income Tax Expense
    		 310K 78K 28K 17K
    Shares Outstanding (Basic)
    		 6.7M 5.93M 2.06M 741.7K
    Shares Outstanding (Diluted)
    		 6.7M 5.93M 2.12M 858.29K
    EPS (Basic)
    		 -5.7 -17.1 -45.6 -119.7
    EPS (Diluted)
    		 -5.7 -17.1 -45.6 -119.7
    EBITDA
    		 -27.58M -107.1M -87.57M -84.54M
    EBIT
    		 -28.37M -107.52M -89.85M -85.04M
    Depreciation & Amortization
    		 796K 419K 1.99M 499K

    Add to Watchlist